• Biotin in STING Assays: Labeling, Controls & Workflow

  2026-08-28

  Biotin (Vitamin B7) can turn a DNA–STING question into a practical capture, competition, and detection workflow, while also supporting enzyme and metabolic assay controls. This guide distinguishes free Biotin from activated biotinylation reagents so researchers can improve signal interpretation without confusing binding chemistry with covalent labeling.

• Neticonazole Hydrochloride: Evidence to Assay

  2026-08-27

  Neticonazole Hydrochloride is an imidazole antifungal with applications spanning cutaneous candidiasis research and preclinical colorectal cancer research. This evidence-to-assay guide explains how to choose clinically relevant fungal endpoints, interpret exosome and apoptosis data, and handle C8715 responsibly.

• Cy5 Hydrazide for Carbonyl Labeling Workflows

  2026-08-27

  Cy5 hydrazide provides a red-fluorescent route to protein carbonylation labeling, glycoprotein analysis, and aldehyde-bearing oligonucleotide detection. Its strong optical response is useful for SDS-PAGE and imaging, while its low aqueous solubility makes solvent handling, cleanup, and nanoparticle compatibility central to reliable results.

• PD 173074: FGFR1 Assay Workflows

  2026-08-26

  PD 173074 combines nanomolar FGFR1 activity with useful VEGFR2 inhibition for dissecting oncogenic signaling, angiogenesis, and resistance phenotypes. This workflow-led guide connects pathway pharmacology with MIR9-driven acute lymphoblastic leukaemia biology and practical assay troubleshooting.

• Puromycin aminonucleoside: Renal Injury Workflow

  2026-08-26

  Build reproducible podocyte injury models with a workflow that connects reagent preparation, pH-sensitive uptake, structural phenotyping, and proteinuria monitoring. This guide also shows how the reference study’s orthogonal biomarker strategy can improve interpretation without overextending glioma findings into renal biology.

• RESTRICT-seq Maps KAT6A in SCC Resistance

  2026-08-25

  The bioRxiv preprint introduces RESTRICT-seq, a time-gated CRISPR screening strategy that separates genetic dependencies involved in establishing squamous cell carcinoma resistance from those required to maintain it. Its prioritization of KAT6A supports a state-aware view of chromatin regulation and provides a rationale for orthogonal validation in cancer biology research.

• Cediranib (AZD2171) in Translational Cancer Research

  2026-08-25

  Cediranib (AZD2171) is more than a potent angiogenesis inhibitor: it is a mechanistic probe for separating VEGFR pathway suppression, endothelial responses, proliferative arrest, and cell death. This thought-leadership guide connects its kinase profile with rigorous in vitro assay design and translational interpretation.

• Tivozanib (AV-951) Assay Design Guide

  2026-08-24

  Build more informative VEGFR-focused cancer assays with Tivozanib (AV-951), from concentration preparation through time-resolved viability and death measurements. This workflow separates growth arrest from cell killing, improving interpretation of renal cell carcinoma and combination-treatment studies.

• Coumestrol Workflows for RA Ferroptosis Research

  2026-08-24

  Coumestrol offers a practical bridge between estrogen receptor biology and ferroptosis-focused rheumatoid arthritis research. This workflow translates RA-FLS findings into reproducible dosing, orthogonal readouts, mechanism validation, and nuclear receptor-aware troubleshooting.

• Pazopanib Hydrochloride In Vitro Workflow

  2026-08-23

  Build more informative oncology assays with Pazopanib Hydrochloride by separating growth arrest from true cell killing. This workflow combines dose-response design, angiogenesis-focused models, paired viability metrics, and practical troubleshooting for renal cell carcinoma and soft tissue sarcoma research.

• Chronic Cabozantinib Remodeling in RCC

  2026-08-22

  A 2026 study used quantitative phosphoproteomics to distinguish acute from chronic Cabozantinib adaptation in renal cell carcinoma cells. It found persistent suppression of activating MET phosphorylation alongside selective adhesion-, stress-, and MAPK/AP-1-associated remodeling, with context-dependent changes in migration and invasion.

• AP20187: Chemical Inducer of Dimerization

  2026-08-22

  AP20187 enables timed activation of engineered fusion proteins for conditional gene expression, regulated cell therapy, and metabolic studies. Its value is greatest when researchers pair a tunable dimerization trigger with orthogonal controls, quantitative reporters, and careful handling of stock solutions.

• AZD3463 for ALK-Driven Cancer Research

  2026-08-21

  AZD3463 is an ALK/IGF1R inhibitor designed for mechanism-focused neuroblastoma studies, from mutation-aware viability assays to pathway and combination-treatment workflows. This guide emphasizes reproducible dosing, solvent control, apoptosis and autophagy readouts, and careful interpretation when extending pathway insights across cancer models.

• ERCC1 Deficiency, p53, and Cisplatin Response

  2026-08-20

  Heyza et al. show that ERCC1 loss does not predict cisplatin sensitivity independently of tumor context: p53 status strongly determines apoptosis, viability, and interstrand-crosslink repair behavior. The study combines CRISPR-engineered lung cancer models with patient survival analyses, providing a framework for interpreting ERCC1 as a platinum-response biomarker.

• PDK4-IN-1 hydrochloride for Metabolic Studies

  2026-08-20

  PDK4-IN-1 hydrochloride gives researchers a selective way to connect PDH activation with mitochondrial energy metabolism, glycolysis, and TCA-cycle behavior. This practical guide covers assay setup, translational workflows, comparative controls, and troubleshooting for metabolic, cardiac, and tumor models.

7426 records 3/496 page Previous Next 12345 下5页 Last page